Hecogenin: A Comprehensive Reference
1. Identity and Chemical Characterization
Names, Synonyms, and Registry Data
Hecogenin is formally identified by the synonyms 12-Oxotigogenin and 3β-Hydroxy-5α-spirostan-12-one, as well as the trade or informal names Gekogenin and Hocogenin. Its CAS Registry Number is 467-55-0, its molecular formula is C27H42O4, and its molecular weight is 430.63 g/mol. The UNII (Unique Ingredient Identifier) assigned by the FDA is 3XP44JJ79F, and the EINECS number is 207-392-4.
Structural Chemistry
Hecogenin is a naturally occurring steroid sapogenin derived from various plant sources. Its unique structure includes a spiro-oxane (spirostanic) framework that contributes to its biological activity. The practical utility of hecogenin as a synthetic starting material is due to the presence of an oxygen atom in the C-12 position that can be relocated to the C-11 position, making it possible to introduce the 9-11 double bond required for the synthesis of corticosteroids.
Hecogenin belongs to the sapogenin class: aglycones (non-saccharide moieties) of saponins, which contain steroid or other triterpene frameworks as their key organic feature. As a spirostanol-type sapogenin, its spiro ring junction at positions 20 and 22 distinguishes it from furostanol sapogenins and contributes to its characteristic physicochemical properties, including low water solubility.
Physical Form and Commercial Preparations
In its purified state, hecogenin appears as a white to slightly yellow crystalline powder. The commercially available form is primarily hecogenin acetate (HA), the acetylated derivative, which is the form in which it is most commonly commercialized. Raw hecogenin is also available at purities ranging from approximately 80% (GC) to 98% (HPLC) for research and industrial applications.
2. Natural Sources and Botanical Origin
Primary Plant Source: Genus Agave
Hecogenin is a steroidal sapogenin largely drawn from the plants of the genus Agave, commonly known as 'sisal', and is one of the important precursors used by the pharmaceutical industry for the synthesis of steroid hormones. It is found abundantly in the leaves of multiple Agave species including Agave sisalana, Agave cantala, Agave aurea, and many more. Additionally, hecogenin has been identified as a major steroidal sapogenin in Agave americana.
Hecogenin is also found in the plant Tribulus terrestris L., which is used as a precursor in the production of steroidal drugs. Hecogenin has a natural occurrence as a product of the senescent metabolism of plants, since it is found mainly in older leaves of Agave sisalana. Analytical studies report a hecogenin concentration of approximately 0.235% in older leaves of Agave sisalana.
Geographic Distribution and Industrial Production
Hecogenin, isolated from sisal leaves found extensively in East Africa, is used for the preparation of cortisone and hydrocortisone hormones. In East Africa, from the leaf 'waste' stripped from leaves during removal of the fibre, a hecogenin-containing 'sisal concentrate' is produced. The 'juice' is separated and allowed to ferment for 7 days; the sludge produced contains about 80% of the hecogenin originally present in the leaves. Steam at 1,380 kPa pressure is employed to complete the hydrolysis of the original glycosides, and by filtration and drying, a concentrate containing about 12% hecogenin and varying amounts of other sapogenins is produced. This crude material is shipped for further processing and cortisone manufacture. Hecogenin is also produced in Israel and China.
In research settings, pure hecogenin has been obtained from sisal waste by selective liquid-liquid extraction of saponins, with a reported yield of 460 mg per kg of sisal waste.
The genus Agave is widely distributed in tropical and subtropical areas, with A. sisalana being a prominent example cultivated for its fiber in countries such as Brazil, India, and parts of Africa.
Co-occurring Sapogenins
Five steroidal sapogenins have been characterised from sisal waste: tigogenin, neotigogenin, hecogenin, gloriogenin, and dehydrohecogenin. A survey of 34 species of Agave conducted in 1978 showed that extracts of most yielded steroidal sapogenins. Tigogenin is frequently found alongside hecogenin in agave-derived extracts, and the two sapogenins require industrial separation procedures for individual purification.
3. Traditional and Historical Use
Mesoamerican and Pre-Columbian Traditions
Agave species — from which hecogenin is derived — have been traditionally used in Mexico since before the arrival of the Spanish. It is believed that the use of these plants dates back to approximately 7,000 BC. When the Spanish arrived in the Americas, they observed the Aztecs using maguey (Agave species) for many purposes. The most commonly used species was Agave pacifica, with which clothing, ropes, and baskets were made. However, the isolation of specific compounds such as hecogenin was not performed by these cultures; the sapogenin content was intrinsically present in preparations made from the whole plant.
Hecogenin is found in aguamiel, the sweet edible sap of mature agave plants, which has long been used in pharmaceutical production and in traditional preparations.
Traditional Medicinal Applications of Agave in India and Africa
In India, the juice of agave leaves has been traditionally used to treat warts and ulcers. Agave species, particularly Agave sisalana, have been utilized since ancient times for fiber and alcohol production. The plant is rich in phytoconstituents that are linked to various medicinal activities. The broader ethnobotanical record of agave-derived preparations for wound healing, anti-inflammatory, and digestive conditions is well documented, though these traditional uses are attributed to the whole plant and its multiple phytochemicals, not to isolated hecogenin specifically.
Industrial History: Corticosteroid Synthesis
In the 1940s, steroidal sapogenins achieved great economic importance because of their transformation into pharmaceutically valuable derivatives such as corticosteroids (prednisone, dexamethasone, betamethasone, triamcinolone, and others), sexual hormones, and steroid diuretics. Among the sapogenins, hecogenin is of prime importance in the synthesis of corticoids. It has been used as a raw material in the production of cortical hormones including cortisone, cortisol, prednisolone, prednisone, dexamethasone, betamethasone, and triamcinolone. Agave sisalana has been cultivated in subtropical America and Kenya specifically as a source of hecogenin, as the starting point in the production of corticosteroids.
Furthermore, hecogenin has been proposed as a competitor to diosgenin — obtained from the dwindling supplies of Dioscoreaceae — in the production of birth-control steroid pills such as oestrogens, progestogens, and 19-norsteroids.
4. Key Constituents, Chemical Forms, and Preparations
Hecogenin (Free Aglycone)
A sapogenin is a constituent of saponins; sapogenins occur naturally in the juice of certain plants in the form of the appropriate water-soluble saponin. A saponin is a member of a group of glycosides, some steroidal derivatives, which are usually characterized by their property of producing a soapy lather. Chemically they consist of multiple sugar groups linked to a sapogenin nucleus by means of a glycosidic bond. Sapogenin (the aglycone) is formed when saponin is hydrolysed. Free hecogenin is thus obtained industrially by acid or steam hydrolysis of naturally occurring hecogenin saponins present in sisal leaf juice.
Hecogenin Acetate (HA)
Hecogenin acetate (HA) is a steroidal sapogenin-acetylated derivative that produces antinociceptive activity and represents the predominant research and commercial form. Hecogenin acetate is a steroidal sapogenin-acetylated with pharmacological properties including anti-inflammatory, anti-hyperalgesic, and antinociceptive effects, but it has low solubility in aqueous media. To address this solubility limitation, inclusion complexes between hecogenin acetate and β-cyclodextrin (β-CD) have been created and evaluated for antinociceptive effects. The complexes were prepared using different methods in molar ratios of 1:1 and 1:2, with the 1:2 (HA:β-CD) ratio prepared by the lyophilization method showing particular promise.
Hecogenin as an Industrial Precursor
Hecogenin with C-ring substitution provides a practical starting material for the synthesis of corticosteroids, whereas diosgenin is more suitable for the manufacture of oral contraceptives and sex hormones. The usefulness of hecogenin as a synthetic starting material is due to the fact that it possesses an oxygen atom in the C-12 position which can be moved to the C-11 position, making it possible to introduce the 9-11 double bond necessary for the synthesis of corticosteroids.
5. Mechanisms of Action
Inflammation: Cytokine and Cellular Pathways
The compounds (hecogenin and its derivatives) can act in different pathologies affecting many systems of the human body. They show pharmacological properties in inflammation, mediating cytokines, cells, and their environment. An anti-inflammatory activity through both cellular and non-cellular components — such as neutrophils and cytokines — has been observed.
In the atopic dermatitis model, treatment with hecogenin (HG) effectively prevented ear thickness, ear weight, hyperplasia, edema, and spongiosis in inflamed tissues, and reduced the production levels of TNF-α and IL-12 in atopic dermatitis-like inflammatory skin. These results indicate that HG is an anti-inflammatory agent through its Th1-skewing reaction, resulting in a reduction of inflammatory reactions and immune cell infiltration.
Gastroprotection: K+ATP Channels and COX-2/Prostaglandin Pathway
Pretreatment with L-NAME (an iNOS inhibitor) and capsazepine (a TRPV1 receptor agonist) were not able to reverse the hecogenin gastroprotective effect, whereas this effect was reversed by glibenclamide, a K+ATP channel blocker, and indomethacin in the model of ethanol-induced gastric lesions. Hecogenin pretreatment normalized GSH levels and significantly reduced lipid peroxidation and nitrite levels in the stomach. The compound alone increased COX-2 expression and this effect was further enhanced in the presence of ethanol. It also decreased myeloperoxidase (MPO) release and significantly protected the gastric mucosa. In conclusion, the gastroprotective effect seems to be mediated by K+ATP channel opening and the COX-2/prostaglandin pathway, with antioxidant and anti-inflammatory properties also playing a role.
Pain/Antinociception: Spinal Cord and Cytokine-Modulatory Mechanisms
Hecogenin acetate (HA) is a steroidal sapogenin-acetylated derivative that produces antinociceptive activity. Studies have evaluated its antihyperalgesic profile in mice in inflammatory models as well as its possible involvement with c-fos expression in the spinal cord and cytokines. Research has proposed that the anti-inflammatory property of hecogenin is produced by COX-2 inhibition, while pretreatment with hecogenin also produced a significant gastroprotective profile mediated by K+ATP channels. The antinociceptive profile of HA appears to be related, at least in part, to a reduction of pro-inflammatory cytokines including IL-1β. Results suggest that HA attenuates mechanical hyperalgesia by blocking the neural transmission of pain at the spinal cord level and through cytokine-inhibitory mechanisms.
Hecogenin and hecogenin acetate have been proposed as alternatives to opioids due to their antagonistic action on pain pathways without motor damage.
Anticancer Pathways
In tumoral processes, hecogenin has participated via pathways including PPARγ, ERK½, and MMP-2. Inhibition of targets such as PPARγ, ERK½, MMP-2, and HER has been associated with potential slowing of tumor progression. In studies comparing plant steroids in human 1547 osteosarcoma cells, all three molecules (including hecogenin) showed an antiproliferative effect. Gel shift analysis demonstrated that none of the plant steroids transactivated PPARγ, but these molecules did induce NF-κB binding to DNA. Although the plant steroids had very close structures, only diosgenin caused a cell cycle arrest associated with strong apoptosis, and hecogenin showed large p53 protein expression but with different dynamics than diosgenin.
Diuretic Mechanism: Aldosterone Synthase Inhibition
Hecogenin (HEC) is a steroidal saponin found in many plant species and serves as a precursor for steroidal drugs. The diuretic effects of HEC and its derivative hecogenin acetate (HA) were largely unexplored until recently. Studies aimed to explore the potential diuretic effects of HEC and HA compared to furosemide and spironolactone. Research published in the Saudi Pharmaceutical Journal (2024) identified aldosterone synthase inhibition as a mechanism underlying the diuretic activity of hecogenin and hecogenin acetate.
UDP-Glucuronosyltransferase Inhibition
Hecogenin is a steroid saponin isolated from Agave sisalana and is a selective inhibitor of human UDP-glucuronosyltransferases (UGTs). Glucuronosyltransferases are responsible for the process of glucuronidation, a major part of phase II metabolism. They are arguably the most important of the phase II (conjugative) enzymes, and the reaction they catalyze involves the addition of a glucuronic acid moiety to xenobiotics, representing the most important pathway for elimination of the most frequently prescribed drugs. Hecogenin's selectivity for specific UGT isoforms has pharmacological and potential drug-interaction relevance.
Antimicrobial Membrane Disruption
Agave sisalana is rich in biomolecules such as saponins and phenolic compounds, with biological activity related to the ability to alter the permeability of fungal and bacterial membranes, leading to cell destruction. The antibacterial activity of hecogenin acetate may be related to its genotoxic potential which promotes a reduction in cell viability and promotes damage both at the DNA level and at the cell wall level, where the sapogenin can produce pores resulting in cell destruction. However, hecogenin acetate does not interfere with the activity of bacterial efflux pumps, which may explain its lack of activity against bacterial strains that use this resistance strategy.
6. Scientific Evidence by Area of Use
6.1 Gastroprotection and Antiulcerogenic Activity
Evidence level: Preclinical (animal and in vitro only); no human clinical trials identified.
Hecogenin has a broad spectrum of pharmacological activities including anti-inflammatory, antifungal, and gastroprotective effects. The most detailed mechanistic investigation used mouse models. Hecogenin presents a significant gastroprotective effect that appears to be mediated by K+ATP channel opening and the COX-2/prostaglandin pathway. Pretreatment reversal by glibenclamide (a K+ATP blocker) and indomethacin in the ethanol-induced gastric lesion model confirmed these pathways.
A 2022 PubMed-indexed study evaluated the antiulcerogenic and healing activity of hecogenin acetate (HA) in acute and chronic models of gastric lesions in rodents. The antiulcerogenic activity of HA was evaluated in models of gastric lesions induced by absolute ethanol and acidified ethanol at doses of 5, 10, and 20 mg/kg. For the ischemia-reperfusion model, rats were pre-treated with HA at 5, 10, and 20 mg/kg and then submitted to 30 minutes of ischemia followed by 1 hour of reperfusion. To evaluate healing activity, gastric ulcer was induced using 80% acetic acid in rats.
All current evidence for gastroprotection originates from rodent models. No randomized controlled trials or human cohort studies on hecogenin for gastric ulcer treatment have been published.
6.2 Anti-inflammatory Activity
Evidence level: Preclinical (animal models and in vitro); no human clinical trials identified.
Hecogenin is a sapogenin found in Agave sisalana species that has been studied for treatment of anti-inflammatory, antifungal, hypotensive, and anti-nociceptive conditions, and cancer. A dedicated study investigated the anti-inflammatory effect of hecogenin and its combination with fluticasone on atopic dermatitis and airway hyper-responsiveness in Balb/c mice. Dermatitis was induced by repeated application of 2,4-dinitrofluorobenzene in Balb/c mice. After topical application of hecogenin, fluticasone, and their combination, ear thickness, ear weight, and erythema score were evaluated. Asthma was induced by sensitization and challenge with ovalbumin. Hecogenin effectively prevented ear thickness and ear weight, and reduced hyperplasia, edema, and spongiosis in inflamed tissues, as well as reducing production levels of TNF-α and IL-12 in AD-like inflammatory skin, indicating an anti-inflammatory agent mechanism through a Th1-skewing reaction.
In vitro anti-inflammatory activity of Agave sisalana acid hydrolysis extract (EAH, which contains hecogenin as a major component) was positive using the human red blood cell membrane stabilization method. In both in vivo tests (carrageenan-induced paw edema and xylene-induced ear edema), EAH at three doses significantly inhibited edema compared to the control group. At a dose of 50 mg/kg, EAH exhibited a greater effect than indomethacin.
6.3 Antinociceptive and Analgesic Activity
Evidence level: Preclinical (mouse models); no human clinical trials identified.
Hecogenin acetate (HA) produces antinociceptive activity. The antihyperalgesic profile of HA was evaluated in mice in inflammatory models, along with its possible involvement with c-fos expression in the spinal cord and cytokines. Acute pretreatment with HA at 5, 10, or 20 mg/kg (i.p.) inhibited the development of mechanical hyperalgesia induced by carrageenan, TNF-α, dopamine, and PGE2. Immunofluorescence data demonstrated that acute pretreatment with HA, at all doses tested, significantly inhibited Fos-like expression in the spinal cord dorsal horn normally observed after carrageenan-induced inflammation.
Moreover, HA did not affect the motor performance of the mice as tested in the Rota rod test. The antinociceptive profile seems to be related, at least in part, to a reduction of pro-inflammatory cytokines, including IL-1β. The results suggest that HA attenuates mechanical hyperalgesia by blocking the neural transmission of pain at the spinal cord level and by cytokine-inhibitory mechanisms.
Evidence for the involvement of descending pain-inhibitory mechanisms was also demonstrated: intraperitoneal administration of hecogenin acetate at 5–40 mg/kg produced a dose-dependent increase in the tail-flick latency time compared to the vehicle-treated group. The periaqueductal gray was implicated in hecogenin acetate-induced antinociception using Fos expression as a marker of neural activation. Mice treated with the compound at 40 mg/kg did not show motor performance alterations.
Formulation research has explored cyclodextrin complexation to improve aqueous solubility: Hecogenin acetate has low solubility in aqueous media, and inclusion complexes with β-cyclodextrin (β-CD) were developed to overcome this barrier and evaluated for antinociceptive effects in orofacial nociception models in mice, prepared at molar ratios of 1:1 and 1:2 by lyophilization.
6.4 Anticancer and Antiproliferative Activity
Evidence level: Preclinical only (in vitro cell lines, in vivo rodent/zebrafish models, in silico). No human clinical trials identified.
Hecogenin has demonstrated a range of pharmacological effects including anti-inflammatory, antioxidant, antifungal, and antiproliferative activities. Despite its broad bioactivity, the precise anticancer mechanisms of hecogenin remain underexplored. An integrative in silico approach has been used to systematically investigate the multi-targeted anticancer potential of hecogenin across six major malignancies: breast cancer, colorectal cancer, leukaemia, osteosarcoma, prostate cancer, and lung cancer.
The antiproliferative activity of hecogenin (HCG) itself remains modest, limiting its potential as an anticancer agent. Therefore, the pursuit of novel HCG derivatives with enhanced antitumour activity is considered important. Fifteen new hecogenin–triphenylphosphonium conjugates were designed, synthesized, and screened for antiproliferative activities. Compound 3c exhibited the best inhibitory activity against human gastric cancer MKN45 cells, induced MKN45 cell apoptosis through the mitochondrial pathway, and inhibited MKN45 cell proliferation in an in vivo zebrafish xenograft model.
A peer-reviewed study showed that inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity, and upregulation of cyclooxygenase-2 (International Journal of Molecular Medicine, 2007).
Notably, all anticancer evidence for hecogenin itself — as opposed to synthetic derivatives — remains at the preclinical stage, and evidence of clinical translation to human subjects is absent.
6.5 Antifungal Activity
Evidence level: In vitro; no human clinical trials identified.
Hecogenin has shown antimicrobial effects against organisms including Candida species and Aedes aegypti larvae. This biological activity is related to the ability of saponins from Agave sisalana to alter the permeability of fungal and bacterial membranes, leading to cell destruction. The antifungal evidence is currently limited to in vitro systems, and translational studies in animal models or clinical populations have not been reported.
6.6 Diuretic and Antihypertensive Activity
Evidence level: Preclinical (animal models); one peer-reviewed pharmacological study (2024). No human clinical trials identified.
Saponins are known for their various biological activities affecting the nervous, cardiovascular and gastrointestinal systems, as well as their involvement in inflammatory and infectious conditions. Hecogenin is a steroidal saponin found in plants of the Agave and Tribulus terrestris L. genus and acts as a precursor in steroidal drug synthesis, naturally present as a byproduct of plant metabolism mainly in older leaves of Agave sisalana. A 2024 study published in the Saudi Pharmaceutical Journal (PMC11170188) examined the diuretic effects of hecogenin and hecogenin acetate, identifying aldosterone synthase inhibition as the underlying mechanism, and comparing efficacy to furosemide and spironolactone in preclinical models.
6.7 Antimicrobial and Antibiotic-Potentiating Activity
Evidence level: In vitro; no human clinical trials identified.
Hecogenin acetate is a sapogenin with significant anti-inflammatory, antifungal, and antimicrobial activity. Natural products with a minimum inhibitory concentration (MIC) greater than 1,000 μg/mL are generally considered to have no relevant bacterial activity for clinical application. The antibacterial activity of hecogenin acetate may be related to its potential to promote damage at both the DNA level and at the cell wall level, producing pores that result in cell destruction. However, hecogenin acetate does not interfere with the activity of bacterial efflux pumps. A 2025 study (published in the Journal of Steroid Biochemistry and Molecular Biology, indexed on PubMed) evaluated hecogenin acetate's ability to modulate the antimicrobial activity of commonly used antibiotics using microdilution techniques with bacterial strains of clinical interest.
7. Body Systems and Health Areas of Association
- Gastrointestinal System: Gastroprotective and antiulcerogenic activity; protection of gastric mucosa via K+ATP channels and COX-2/prostaglandin pathways.
- Immune/Inflammatory System: Modulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-12); inhibition of neutrophil recruitment; attenuation of atopic dermatitis-like inflammation.
- Nervous System (Pain): Antinociceptive and anti-hyperalgesic effects via spinal cord inhibitory mechanisms; involvement of descending pain-inhibitory pathways including the periaqueductal gray.
- Cardiovascular/Renal System: Diuretic effects via aldosterone synthase inhibition; antihypertensive properties.
- Oncology (Preclinical): Antiproliferative activity in osteosarcoma, gastric cancer, and rheumatoid arthritis synovial cells; modulation of PPARγ, ERK½, MMP-2, and NF-κB pathways.
- Infectious Disease (Antifungal/Antimicrobial): Activity against Candida spp. and certain bacteria through membrane disruption; antibiotic-potentiating properties in vitro.
- Drug Metabolism: Selective inhibition of human UDP-glucuronosyltransferases, implicating hecogenin in phase II metabolic drug interactions.
- Endocrine/Pharmaceutical: Historical and ongoing use as an industrial precursor for corticosteroids, sex hormones, and steroid diuretics.
8. Dosages Reported in Scientific Studies
All dosages below are as reported in published preclinical research; no approved therapeutic dosing guidance for human use exists, and no clinical trials in humans have established efficacious or safe human doses for hecogenin as a standalone supplement.
- Hecogenin acetate — antinociception (mice, i.p.): Acute pretreatment with HA at 5, 10, or 20 mg/kg intraperitoneally inhibited the development of mechanical hyperalgesia induced by carrageenan, TNF-α, dopamine, and PGE2.
- Hecogenin acetate — tail-flick antinociception (mice, i.p.): Intraperitoneal administration of hecogenin acetate at 5–40 mg/kg produced a dose-dependent increase in the tail-flick latency time, without motor performance alterations at 40 mg/kg.
- Hecogenin acetate — antiulcerogenic (rats, oral): The antiulcerogenic activity of HA was evaluated at doses of 5, 10, and 20 mg/kg in models of gastric lesions induced by ethanol. To evaluate healing activity, gastric ulcers were induced using 80% acetic acid, after which animals were treated for 7 consecutive days with HA at 10 and 20 mg/kg.
- Agave sisalana hydrolysis extract (EAH) — anti-inflammatory (rats, oral): At a dose of 100 mg/kg by repeated doses, reproductive toxicity effects were assessed. At 50 mg/kg, EAH exhibited a greater anti-inflammatory effect than indomethacin.
9. Safety Considerations
Reproductive Toxicity
In vivo toxicological studies showed that an Agave sisalana hydrolysis extract (EAH), rich in steroidal sapogenins including hecogenin, does not present toxic effects when administered orally in a single dose up to 1,000 mg/kg. However, EAH promoted a gonadotoxic effect and increased the embryonic mortality rate after implantation. While the extract can be considered a potential anti-inflammatory agent, it presented a powerful reproductive toxic effect in rats, and further studies are needed to elucidate the chemical composition. This finding is a significant safety concern that warrants attention pending further characterization.
Absence of Cytotoxic and Clastogenic Potential (in vitro)
The acid hydrolysis extract of sisal juice did not show cytotoxic and clastogenic potentials in relevant assessments; however, it presented a powerful reproductive toxic effect in rats. This underscores the importance of further studies to elucidate the full chemical composition of sisal juice and its biological effects.
Drug Metabolism Interactions (UGT Inhibition)
Hecogenin is a selective inhibitor of human UDP-glucuronosyltransferases (UGTs). The reaction catalyzed by the UGT enzyme represents the most important pathway for the human body's elimination of the most frequently prescribed drugs, and is the major pathway for removal of drugs, dietary substances, toxins, and endogenous substances. Inhibition of UGT enzymes by hecogenin is therefore a pharmacokinetic interaction risk of clinical significance: if hecogenin is consumed alongside drugs that are primarily glucuronidated, plasma levels and potential toxicity of those drugs could increase. This is an area of concern identified in the scientific literature that requires further pharmacokinetic study.
Anti-edematogenic vs. Reproductive Toxicity Trade-off
The anti-edematogenic effect of the acid hydrolysis extract from sisal juice is attributed to the high concentration of steroidal sapogenins, and this extract can be considered a potential new anti-inflammatory. However, the same extract demonstrated reproductive toxicity in animal studies, highlighting a significant safety trade-off that has not been characterized in human subjects.
Motor Function (Preclinical — Not Impaired)
In preclinical antinociceptive studies, HA did not affect the motor performance of mice as tested in the Rota rod test, suggesting that at the doses tested in mice, motor toxicity was not observed. This result has not been translated to human safety data.
Absence of Human Clinical Safety Data
A 2023 systematic pharmacology review of hecogenin and its derivatives (published in Biomedicine & Pharmacotherapy, PubMed ID 36641922) confirmed that all pharmacological and safety data to date come from preclinical (in vitro and animal) studies. This compilation shows that the compounds can act in different pathologies affecting many systems of the human body; they show pharmacological properties in inflammation, tumoral processes, and antimicrobial effects. The review indicates that continuing studies with these molecules are essential, as they have the potential to become future drugs. No Phase I, II, or III clinical trials investigating hecogenin as a therapeutic agent in humans have been identified in the published literature.
References
Go back